Human RCTPubMed ID: 17264618·2007

REDUCE-2: Sustained Tesamorelin Effects on Visceral Adiposity in HIV Lipodystrophy

Falutz J, Allas S, Bloch M, et al.

AIDS, 2007 · n = 339

Key finding

Tesamorelin achieved 19.2% visceral AT reduction versus 9.1% placebo (p<0.001) with benefits maintained upon treatment continuation.

Summary

Second pivotal Phase 3 trial confirming tesamorelin visceral fat reduction with extended follow-up through 52 weeks.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TesamorelinL5

An FDA-approved GHRH analog used for HIV-associated lipodystrophy, with research into broader metabolic and cognitive applications.

More research on Tesamorelin

Tesamorelin Reduces Visceral Adiposity Independently of Changes in Appetite or Food Intake

Journal of Acquired Immune Deficiency Syndromes · 2016 · Human RCT

Tesamorelin Effects on Hepatic Steatosis in HIV-Positive Patients: Ultrasound and Transient Elastography Study

Journal of Hepatology · 2015 · Human RCT

Tesamorelin Effects on Serum Lipids and Apolipoprotein Profile in HIV Lipodystrophy

Journal of Lipid Research · 2014 · Human RCT

Tesamorelin Reduces Cardiovascular Risk Markers in HIV-Associated Lipodystrophy

The Journal of Clinical Endocrinology & Metabolism · 2013 · Human RCT

Hepatic and Renal Function During Tesamorelin Treatment in HIV-Positive Patients

Journal of Acquired Immune Deficiency Syndromes · 2013 · Human RCT